Pre-earnings options volume in FibroGen is normal with calls leading puts 43:1. Implied volatility suggests the market is anticipating a move near 25.4%, or 0c, after results are released. Median move over the past eight quarters is 8.6%.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FGEN:
- FGEN Upcoming Earnings Report: What to Expect?
- FibroGen ends pamrevlumab R&D after study results, cutting 75% of U.S workers
- FibroGen: LAPIS study did not meet the primary endpoint of OS
- FibroGen trading resumes
- FibroGen Announces Topline Results from Two Late-Stage Pamrevlumab Pancreatic Cancer Studies and Provides Corporate Update